Deadline: 17-Aug-2025
The Indian Council of Medical Research (ICMR), New Delhi, is inviting Expressions of Interest (EoI) from eligible organizations, companies, and manufacturers for the transfer of technology and commercialization of a recombinant chimeric multi-stage malaria vaccine, AdFalciVax. This vaccine is designed to prevent Plasmodium falciparum infection in humans and reduce its transmission within communities.
The objective is to license the technology for AdFalciVax to commercial partners who will undertake marketing and development activities. ICMR is looking to collaborate with capable entities for the further development, manufacture, sale, and commercialization of this vaccine. Agreements will be executed on a non-exclusive basis to ensure broad outreach and public health impact. All engagements will adhere to ICMR’s IP Policy.
ICMR’s Regional Medical Research Center in Bhubaneswar holds technical expertise relevant to the vaccine’s production and will provide guidance across all phases of development. The center, along with other ICMR institutes, will support activities including study planning, product development, protocol design, data analysis, and efficacy and safety evaluations. The collaboration will also extend to facilitating R&D and clinical studies in India, based on mutual agreement and clearly defined timelines.
ICMR will offer technical assistance and may support validation activities as outlined in the formal agreement. There will be no financial obligation on ICMR unless explicitly stated otherwise.
Interested proponents must meet general pre-qualification criteria. They must be legal entities registered in India, have relevant manufacturing or R&D experience over the past three years, and a history of marketing similar products. Financially, they must not have incurred overall losses in the past three years and should not be blacklisted by any government entity. Additionally, they must have a manufacturing unit in India and must not have legal convictions in the past three years. Quality certifications such as GMP or ISO are required for manufacturing and R&D operations.
Specific criteria include having a functional R&D lab and the capacity to produce a specified quantity of the vaccine weekly.
Applications will be rejected if they are not in the prescribed format, lack necessary documentation, are submitted late, or fail to meet the requirements stated in the EoI. Any material deviation or non-compliance will also lead to disqualification.
For more information, visit ICMR.
